Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells

Cristina Corno, Laura Gatti, Cinzia Lanzi, Nadia Zaffaroni, Diego Colombo, Paola Perego

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl biological functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors tailored to this receptor tyrosine kinase.

Original languageEnglish
Pages (from-to)1496-1512
Number of pages17
JournalCurrent Medicinal Chemistry
Volume23
Issue number15
Publication statusPublished - May 1 2016

Fingerprint

Tumors
Cells
Receptor Protein-Tyrosine Kinases
Chemical activation
Neoplasms
Cell proliferation
Phosphatidylinositol 3-Kinases
Antineoplastic Agents
Cell Movement
axl receptor tyrosine kinase
Cell Survival
Cell Proliferation
Molecules
Pharmaceutical Preparations
Therapeutics

Keywords

  • Axl
  • Cancer
  • Drug resistance
  • Inhibitors.
  • Invasion
  • Receptor tyrosine kinases

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells. / Corno, Cristina; Gatti, Laura; Lanzi, Cinzia; Zaffaroni, Nadia; Colombo, Diego; Perego, Paola.

In: Current Medicinal Chemistry, Vol. 23, No. 15, 01.05.2016, p. 1496-1512.

Research output: Contribution to journalReview article

@article{712f5d2fbb114b33af9299932d8c8fde,
title = "Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells",
abstract = "Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl biological functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors tailored to this receptor tyrosine kinase.",
keywords = "Axl, Cancer, Drug resistance, Inhibitors., Invasion, Receptor tyrosine kinases",
author = "Cristina Corno and Laura Gatti and Cinzia Lanzi and Nadia Zaffaroni and Diego Colombo and Paola Perego",
year = "2016",
month = "5",
day = "1",
language = "English",
volume = "23",
pages = "1496--1512",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells

AU - Corno, Cristina

AU - Gatti, Laura

AU - Lanzi, Cinzia

AU - Zaffaroni, Nadia

AU - Colombo, Diego

AU - Perego, Paola

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl biological functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors tailored to this receptor tyrosine kinase.

AB - Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl biological functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors tailored to this receptor tyrosine kinase.

KW - Axl

KW - Cancer

KW - Drug resistance

KW - Inhibitors.

KW - Invasion

KW - Receptor tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=84974603298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974603298&partnerID=8YFLogxK

M3 - Review article

VL - 23

SP - 1496

EP - 1512

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 15

ER -